PALO ALTO, Calif.--(BUSINESS WIRE)--Carmenta Bioscience, Inc., a privately held medical technology company focused on maternal and fetal health, today announced it has acquired the option for a worldwide, exclusive license from Stanford University to develop a set of tests enabling physicians to better diagnose and predict preeclampsia. Preeclampsia is a leading cause of preterm birth and maternal/fetal death, arising in 5-8% of pregnant mothers and characterized by high blood pressure and protein in the urine after week 20 of pregnancy.